摘要
为了研究CALM和AF10融合转录在原发性t( 10 ;11)易位白血病形成和治疗中的作用 ,采用RT PCR技术检测了 5例原发性t( 10 ;11)易位白血病患者CALM AF10融合转录 ,体外MTT法检测了其白血病细胞体外化疗敏感性。结果表明 :在 5例原发性t( 10 ;11)易位白血病患者中检测到 5种分子量的AF10 CALM融合转录和 4种分子量的CALM AF10融合转录 ;MTT法显示 5例原发性t( 10 ;11)易位白血病患者的白血病细胞有 2例对体外化疗敏感 ( 60 % ) ,3 6例非t( 10 ;11)易位白血病细胞有 3 1例对体外化疗敏感 ( 86% ) ,统计分析有显著差异 (P <0 0 1) ,与临床治疗结果一致。化疗药物处理 72小时 ,t( 10 ;11)白血病细胞的凋亡率为 ( 16.3 7± 2 .5 6) % ,而非t( 10 ;11)白血病细胞的为 ( 3 3 .75± 5 .5 9) % ,差异有显著性 (P <0 .0 1)。结论 :CALM AF10是t( 10 ;11)易位白血病的常见特点之一 ,可能与该白血病发生密切相关 ,且t( 10 ;11)易位白血病患者预后较差。
In order to determine the involvement of CALM AF10 fusion transcripted in primary leukaemias with t(10;11) and its chemotherapy sensitivity in vitro, the AF10 CALM fusion transcripts were detected by reverse transcription polymerase chain reaction (RT PCR), and the chemotherapy sensitivity testing in vitro was undergone by MTT assay in five t(10;11) leukemia samples from patients with ALL, AML and lymphoblastic lymphoma. The results showed that five different sized AF10 CALM product and four different sized CALM AF10 products were detected. The chemotherapy sensitivity of leukemic cells with t(10;11) in vitro to drugs is lower than that of leukemic cells without t(10;11) . 3 out of 5 cases of t(10;11) leukemia were sensitive to chemotherapeutic drugs, while 31 out of 36 cases of leukemia without t(10;11) were sensitive at same condition. There were significant differences (P<0.01), consistent with clinical features of patients. Apoptosis rate of leukemic cells with t(10;11) induced by chemotherapeutic drugs was lower than that of leukemic cells without t(10;11), (16.37±2.56)%, and (33.75±5.59)%, respectively (P<0 01). It is concluded that the CALM AF10 fusion transcripts are a common features and are involved in the pathogenesis of haematological malignancies with t(10;11), and are associated with a poor prognosis.
出处
《中国实验血液学杂志》
CAS
CSCD
2004年第6期770-773,共4页
Journal of Experimental Hematology
